Search

everythinglearnresearchcommunity

for

Search:↓

Type 2 diabetes in youth is increasing, with high treatment failure rates and more severe than Type 1; certain drugs can lower lipid levels effectively with varying side effects, and apples may benefit heart health like statins but with fewer side effects.

Metformin helps with menstrual cycles and insulin levels in PCOS but is less effective for hair growth, diabetes prevention, and weight loss, and may improve fertility and reduce diabetes risk.

Men with early hair loss have similar hormone levels to women with PCOS, possibly increasing risk of obesity and heart issues.

Both treatments reduced excessive hair growth in PCOS, but there was no difference in weight, hair score, hormone levels, or insulin resistance.

Finasteride-treated male rats' offspring had altered glucose metabolism, potentially increasing diabetes risk.

There's no significant link between blood fat levels and male pattern baldness.

Women with PCOS and higher androgen levels are more likely to have fatty liver disease.

Isotretinoin improves severe acne without changing androgen or insulin levels but may increase body weight and triglycerides.

Women with PCOS and polycystic ovaries have higher male hormone levels and more insulin resistance, especially if they are overweight.

People with hair loss have higher risk of high blood sugar and diabetes, and lower levels of a specific hormone.

Brazilian women with PCOS and both menstrual irregularity and high male hormone levels have a higher chance of having metabolic syndrome.

Women with PCOS often have insulin resistance, abnormal lipid levels, and a higher risk of diabetes and heart disease; lifestyle changes and medication like metformin can help manage these risks.

Metformin and rosiglitazone improve blood vessel function in women with PCOS, with metformin also reducing insulin resistance and testosterone levels.

To diagnose Polycystic Ovarian Syndrome, two out of three signs—irregular periods, high male hormone levels, or cysts on the ovaries—are needed.

Women with PCOS are more likely to have insulin resistance and obesity, especially those with the most severe type I PCOS.

Mild thyroid issues don't affect the metabolism and hormones of women with PCOS.

Metformin helps manage polycystic ovary syndrome by improving insulin resistance and ovulation, but more research is needed on its full effects.

The document concludes that early recognition and treatment of PCOS in adolescents is crucial for managing symptoms and long-term health risks.

Blocking a specific enzyme might help treat obesity and diabetes, but more research is needed to ensure it's safe.

Women with acromegaly often have irregular periods due to hormone imbalances and growth hormone effects.

Targeting glucocorticoid action might help treat type-2 diabetes, but human trials are needed.

Women with PCOS are more likely to have fatty liver disease and worse metabolic health.

STK11 gene variations do not predict how well metformin will work for PCOS, but may affect hair loss and excess hair growth.

Surgery to lower high testosterone in postmenopausal women with certain ovarian tumors doesn't significantly affect their metabolism.

Taking 5α-reductase inhibitors with prednisolone can worsen its negative effects on metabolism.

Older people tend to have higher biotin levels, which are weakly linked to certain blood components and negatively linked to triglycerides; biotin should be checked in patients with high triglycerides or medication-related skin issues, and only supplemented if deficient. Vitamin D and folate deficiencies are linked to specific skin conditions.

Tacrolimus causes fewer acute rejections than cyclosporin A in kidney transplants but doesn't necessarily improve kidney function after one year; cardiovascular risks and side effects vary between the two drugs.

Insulin resistance is linked to larger thyroid volume in patients with polycystic ovary syndrome.

Adequate vitamin D might lower, and high hair chromium might increase DNA damage in obese women.

Endovascular repair and open surgery for abdominal aortic aneurysms both result in a temporary decline in physical health, with no significant mental health difference, and a return to near normal health in 90 days.